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S U M M A R Y
In spite of the recent introduction of two new drugs (delamanid and bedaquiline) and a few repurposed
compounds to treat multidrug-resistant and extensively drug-resistant tuberculosis (MDR- and XDR-
TB), clinicians are facing increasing problems in designing effective regimens in severe cases. Recently a
9 to 12-month regimen (known as the ‘Bangladesh regimen’) proved to be effective in treating MDR-TB
cases. It included an initial phase of 4 to 6 months of kanamycin, moxiﬂoxacin, prothionamide,
clofazimine, pyrazinamide, high-dose isoniazid, and ethambutol, followed by 5 months of moxiﬂoxacin,
clofazimine, pyrazinamide, and ethambutol. However, recent evidence from Europe and Latin America
identiﬁed prevalences of resistance to the ﬁrst-line drugs in this regimen (ethambutol and
pyrazinamide) exceeding 60%, and of prothionamide exceeding 50%. Furthermore, the proportions of
resistance to the two most important pillars of the regimen – quinolones and kanamycin – were higher
than 40%. Overall, only 14 out of 348 adult patients (4.0%) were susceptible to all of the drugs composing
the regimen, and were therefore potentially suitable for the ‘shorter regimen’. A shorter, cheaper, and
well-tolerated MDR-TB regimen is likely to impact the number of patients treated and improve
adherence if prescribed to the right patients through the systematic use of rapid MTBDRsl testing.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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The World Health Organization (WHO) recently published its
End TB Strategy, stressing the importance of diagnosing, treating,
and preventing both multidrug-resistant (MDR)- and extensively
drug-resistant (XDR-) tuberculosis (TB).1–3 MDR-TB is deﬁned as
resistance to at least rifampicin and isoniazid, the two most
effective anti-TB drugs, while XDR-TB is a more severe form of§ The authors alone are responsible for the views expressed in this article and
they do not necessarily represent the decisions and policies of their institutions.
* Corresponding author.
E-mail address: giovannibattista.migliori@fsm.it (G.B. Migliori).
1 Giovanni Sotgiu, Simon Tiberi, Rosella Centis, and Lia D’Ambrosio contributed
equally.
Please cite this article in press as: Sotgiu G, et al. Applicability o
tuberculosis settings. Int J Infect Dis (2017), http://dx.doi.org/10.101
http://dx.doi.org/10.1016/j.ijid.2016.10.021
1201-9712/ 2016 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).MDR-TB with additional resistance to any ﬂuoroquinolone and to
injectable second-line drugs (amikacin, capreomycin, kanamycin).
The Strategy also states the possibility of eliminating TB
through the implementation of speciﬁc interventions that are
currently recommended for low TB incidence countries.4,5 Among
the eight core interventions, the management of MDR-TB has an
important role.4,5
MDR- and XDR-TB represent a growing clinical and public
health concern, with over 480 000 cases and 190 000 deaths
estimated to have occurred globally in 2014.1 In spite of the
progress achieved,6 only a proportion of existing MDR- and XDR-
TB cases have access to quality diagnosis1,7 and treatment, with
treatment being long (up to 24 months), expensive, and
complicated by severe adverse events.2,3,6–12 Furthermore, treat-
ment outcomes are still unsatisfactory, with treatment successf the shorter ‘Bangladesh regimen’ in high multidrug-resistant
6/j.ijid.2016.10.021
ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
G. Sotgiu et al. / International Journal of Infectious Diseases xxx (2017) xxx–xxx2
G Model
IJID-2752; No. of Pages 4rates remaining suboptimal, and success rates decreasing progres-
sively from 50% in MDR-TB cases to 40% in XDR-TB cases and less
than 20% in cases with resistance patterns beyond XDR-TB.2,3,13,14
Following more than 40 years of neglect since the launch on the
market of the last TB-speciﬁc drug (rifampicin), the available
armamentarium of anti-TB drugs currently includes two new
drugs (delamanid and bedaquiline) and a few repurposed
compounds.9,15–25 As clinical experience with these new drugs
and some of the repurposed drugs is still limited, and the number
of drugs for which susceptibility is conﬁrmed is often very
limited,20–22 clinicians face more and more difﬁculties in designing
effective regimens as per WHO guidelines.16
Recent evidence suggests that a 9 to 12-month regimen (known
as the ‘Bangladesh regimen’) may be effective in treating MDR-TB
cases (Table 1).26–28
As part of the ALAT/ERS LATSINTB project (a research coordina-
tion project), the present article describes the rationale for the
introduction of the Bangladesh or ‘shorter regimen’ to treat MDR-
TB, the principles of the new 2016 WHO recommendations, and the
main operational issues related to their implementation under
programmatic conditions in high MDR-TB prevalence settings.
2. Rationale for the shorter regimen and the new WHO
guidelines
The rational composition of this new regimen is similar to that
of the traditional 24-month one, with a consistent number of drugs
and the inclusion of a ﬂuoroquinolone, a second-line injectable
drug, and two other ‘companion’ drugs (e.g., drugs supporting the
core drugs to prevent the selection of drug-resistant
mutants).13,15,16 However, in the new regimen moxiﬂoxacin is
‘the’ ﬂuoroquinolone, while clofazimine replaces cycloserine. The
Bangladesh regimen includes an initial phase of 4 to 6 months ofTable 1
Evidence available on the efﬁcacy and safety of the shorter regimen (known as the Ba
Study (Ref.) Setting/number of cases Study results 
Piubello et al.
Int J Tuberc
Lung Dis 2014 (26)
Niger National Tuberculosis
Programme; 65 MDR-TB patients
Cure was achieved in 58 p
(89.2%, 95% CI 81.7–96.7)
and 1 defaulted; all 49 pa
assessed at the 24-month
follow-up after cure rema
smear- and culture-negat
Van Deun et al.
Am J Respir Crit
Care Med 2010 (27)
Prospective observational study
conducted over a 12-year period
in this large TB control program
in Bangladesh; 427 MDR-TB
patients
206/427 (48.2%) patients
received the most effectiv
treatment regimen; a min
of 9 months of treatment
GFX, CFZ, EMB, and PZA
throughout the treatmen
period, supplemented by
KM, and high-dose INH du
intensive phase of a minim
4 months, giving a relaps
cure of 87.9% (95% CI 82.7
Aung et al.
Int J Tuberc Lung
Dis 2014 (28)
Bangladesh National
Tuberculosis Programme;
prospective, observational study
of a GFX-based directly observed
regimen, mainly with initial
hospitalization; 515 MDR-TB
patients
515 patients were recruite
2005 to 2011, 84.4% had 
bacteriologically favourab
outcome; due to extensiv
disease with delayed spu
conversion, only half of t
patients completed treatm
within 9 months; 95% com
treatment within 12 mon
11 patients failed or relap
and 93.1% of the 435 pat
who were successfully tr
completed at least 12 mo
post-treatment follow-up
CFZ, clofazimine; CI, conﬁdence interval; EMB, ethambutol; FQ, ﬂuoroquinolone; G
tuberculosis; OFX, oﬂoxacin; PTO, prothionamide; PZA, pyrazinamide; TB, tuberculosis
Please cite this article in press as: Sotgiu G, et al. Applicability o
tuberculosis settings. Int J Infect Dis (2017), http://dx.doi.org/10.101kanamycin, gatiﬂoxacin, prothionamide, clofazimine, pyrazina-
mide, high-dose isoniazid, and ethambutol, followed by 5 months
of gatiﬂoxacin, clofazimine, pyrazinamide, and ethambutol.13,14,16
Based on the available evidence, the WHO has recommended
this shorter MDR-TB regimen in its new 2016 MDR-TB guidelines,
with moxiﬂoxacin replacing gatiﬂoxacin (originally used in the
Bangladesh regimen).
The new regimen, which is much cheaper than longer ones
(<1000 dollars),8,16 is indicated only for ‘‘adults and children with
rifampicin-resistant and MDR-TB who have not been previously
treated with second-line drugs and in whom resistance to
ﬂuoroquinolones and second-line injectable agents have been
excluded or considered highly unlikely’’.16 The indication also
includes people living with HIV/AIDS.16 A summary of the
composition of the regimen and a list of the recommended
exclusion criteria for the shorter TB regimen in favour of the longer
regimen are given in Table 2.
The same WHO guidelines recommend a diagnostic tool
designed to speed up the detection of TB resistance – the rapid
molecular MTBDRsl test.16 The promotion of broader and quicker
molecular testing will ensure the appropriate selection of patients
who will beneﬁt from the shorter MDR-TB regimen, while reducing
the ‘infectious period’ and the subsequent transmission of resistant
strains of Mycobacterium tuberculosis within the community.
Furthermore, the rapid initiation of an adequate regimen will
minimize the possible development of additional drug resistance
(‘super-resistance’), which is among the criteria deﬁning ‘treat-
ment failure’ in the 2015 WHO deﬁnitions.1
3. Operational issues and evidence of eligibility for the shorter
regimen
This is a concrete demonstration of the genuine efforts being
made to provide wider access to quality MDR-TB diagnostic andngladesh regimen) to treat multidrug-resistant tuberculosis
Conclusions Comments
atients
; 6 died
tients
ined
ive
Standardized 12-month treatment
for MDR-TB was highly effective and
well tolerated in patients not
previously exposed to second-line
anti-TB drugs in Niger
The main adverse events were
vomiting (26.2%) and hearing
impairment (20%), but no
treatment had to be stopped;
1 patient HIV-infected (1.7%)
e
imum
 with
t
 PTO,
ring an
um of
e-free
–91.6)
Serial regimen formulation guided
by overall treatment effectiveness
resulted in treatment outcomes
comparable to those obtained with
ﬁrst-line anti-TB treatment;
conﬁrmatory formal trials in
populations with high levels of HIV
co-infection and in populations with
a higher initial prevalence of
resistance to second-line anti-TB
drugs are required
Major adverse drug reactions
were infrequent and manageable
Compared with the 221 patients
treated with regimens based on
OFX and commonly PTO
throughout, the hazard ratio of
any adverse outcome was 0.39
(95% CI 0.26–0.59)
d from
a
le
e
tum
he
ent
pleted
ths;
sed,
ients
eated
nths of
The excellent outcome of the
Bangladesh regimen was largely
maintained; bacteriological
treatment failures and relapses
were rare, except among patients
with high-level GFX resistance,
notably in the presence of PZA
resistance
The strongest risk factor for a
bacteriologically unfavourable
outcome was high-level FQ
resistance, particularly when
compounded by initial PZA
resistance
Low-level FQ resistance had no
unfavourable effect on treatment
outcome
Ampliﬁcation of drug resistance
occurred only once, in a patient
strain that was initially only
susceptible to KM and CFZ
FX, gatiﬂoxacin; INH, isoniazid; KM, kanamycin; MDR-TB, multidrug-resistant
.
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Table 2
Composition of the shorter regimen (known as the Bangladesh regimen) to treat multidrug-resistant tuberculosis, and the main contraindications suggesting prescription of
the longer regimena
Composition
4–6 Km–Mfx–Pto–Cfz–Z–Hhigh-dose–E/5 Mfx–Cfz–Z–E: 4 to 6 months of kanamycin, moxiﬂoxacin, prothionamide, clofazimine, pyrazinamide, high-dose isoniazid,
and ethambutol, followed by 5 months of moxiﬂoxacin, clofazimine, pyrazinamide, and ethambutol
Contraindication Comments
Conﬁrmed resistance to or suspected ineffectiveness of a drug in the
shorter MDR-TB regimen (except isoniazid resistance)
Evaluation of the drug resistance pattern of all patients with
rapid diagnostic methods is recommended
Exposure to 1 second-line drugs in the shorter MDR-TB regimen for >1 month
Intolerance to 1 drugs in the shorter MDR-TB regimen or risk of toxicity
(e.g., drug–drug interactions)
Intolerance to a drug composing the regimen is, in practice,
equivalent to resistance to the drug
At least one drug in the shorter MDR-TB regimen not available
Pregnancy Insufﬁcient evidence available
Extrapulmonary disease Insufﬁcient evidence available
MDR-TB, multidrug-resistant tuberculosis.
a Note: The emergence of treatment failure, drug intolerance, return after an interruption >2 months, or emergence of any other exclusion criterion implies interruption of
the shorter regimen and a move to the longer one.
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ing the endorsement of the shorter MDR-TB regimen, clinicians
and public health experts have started posing three questions:
(1) Under programmatic conditions, what is the proportion of
patients who might not be eligible for the shorter regimen in
reference centres or settings concentrating on difﬁcult-to-treat
MDR-TB cases (e.g., those exposed to several previous rounds of
treatment or with previous treatment failure)? In other words,
what proportion of cases will be eligible for treatment with the
shorter MDR-TB regimen in programmatic (non research)
settings?
(2) In countries or settings with sub-optimal laboratory services,
will it be possible to use the shorter regimen based on
epidemiological surveillance data or periodic drug resistance
surveys?
(3) In the case of resistance to one or two of the drugs in the
regimen, can compromised drugs be substituted in order to
maintain the efﬁcacy of the regimen, and if so, to what extent?
In summary, the regimen is for MDR-TB cases not previously
treated with second-line anti-TB drugs and, therefore, should not
be used in the case of (a) previous use of any of the Bangladesh
regimen drugs, and (b) documented or suspected resistance to one
or more of them.16
Initial evidence is available only for the ﬁrst question. A recent
multi-centre, observational, retrospective, cohort study of the
International Carbapenems Study Group (ICSG) was conducted in
reference MDR-TB centres in Europe (eight countries) and Latin
America (three countries).13,14 All of the drugs in the Bangladesh
regimen were routinely tested in the participating centres, except
high-dose isoniazid and clofazimine. The study found that only
14 out of 348 adult patients (4.0%) were susceptible to all of the
drugs, and were therefore potentially suitable for the ‘shorter
regimen’.13 Interestingly, the prevalence of resistance to the ﬁrst-
line drugs in the regimen (ethambutol and pyrazinamide)
exceeded 60% and that of prothionamide exceeded 50%. Further-
more, the proportion of resistance to the two most important
pillars of the regimen – quinolones and kanamycin – exceeded 40%.
The prevalence of resistance to these two drugs was higher in Latin
American than in Europe. The authors concluded that the shorter
MDR-TB regimen ‘‘would have an impact on only minority of
patients and may have limited use in these settings where patients
have more resistant forms of TB and are more treatment
experienced (like in reference centres)’’. However, the limited
sample size, non-representativeness of the data with the
possibility of selection bias, and the limited reliability of drugPlease cite this article in press as: Sotgiu G, et al. Applicability o
tuberculosis settings. Int J Infect Dis (2017), http://dx.doi.org/10.101susceptibility testing to pyrazinamide and ethambutol (even when
performed in quality assured laboratories) should be considered
when interpreting the results of that study. In addition, no reliable
drug susceptibility testing is yet available for clofazimine and
ethionamide.13
This study conﬁrmed the results of previous non-representative
cohorts that identiﬁed prevalence rates around 30% for ﬂuor-
oquinolones, 60% for ethambutol, 70% for pyrazinamide, 45% for
prothionamide and 70% for kanamycin in a sample of patients in
Europe, with strong representation of MDR-TB hot spots like
Romania and former Soviet Union countries.29 As these studies
were not designed to evaluate the Bangladesh regimen, they did
not provide information on how many patients would potentially
have beneﬁtted from the regimen.
A ﬁnal comment is that we need more information on the
suitability of patients for high-dose isoniazid. The existing
evidence suggests that high-dose isoniazid is effective in the
presence of the inhA gene mutation and in absence of the katG
mutation. This combination is estimated to be present in no more
than 12% of patients globally, with lower values in Africa.
The answer to question 2 is not available, and it is the authors’
opinion that caution is needed in assuming that no drug resistance
exists in low MDR-TB prevalence settings; testing all cases is the
best option.
As far as question 3 is concerned, it is likely that kanamycin will
be replaced by capreomycin or amikacin, although these mod-
iﬁcations will increase the cost of the regimen.13 It is also possible
that, in view of resistance to one or more drugs in the regimen,
clinicians might decide to replace them with the new drugs
(delamanid, bedaquiline) or with the most effective repurposed
drug (although more prone to adverse events), e.g. linezolid. It is
important to underline that these changes are not recommended,
as no evidence currently exists regarding the possibility of
modifying the regimen with these drugs while keeping the short
duration proﬁle (and ensuring tolerability, efﬁcacy, and adher-
ence).13
4. Conclusions
In conclusion, a shorter, cheaper, and well-tolerated MDR-TB
regimen is likely to impact the number of patients treated and
improve adherence.13,14 The preliminary evidence available on the
country- or setting-speciﬁc prevalence of resistance to the drugs in
the regimen needs to be expanded, taking into account that high
combined resistance to ﬂuoroquinolones and pyrazinamide might
represent the main limitation to the success of the new
regimen.28,30f the shorter ‘Bangladesh regimen’ in high multidrug-resistant
6/j.ijid.2016.10.021
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regimen will be the systematic use of rapid MTBDRsl testing, so
that the regimen is prescribed to the correct patients.
The increasing possibility of dosing blood levels of the different
drugs through therapeutic drug monitoring (TDM) will further
improve the tolerability of the shorter regimen (as well as that of
the longer one) in the coming future, while increasing treatment
adherence.
Importantly, the role of expert discussion (cohort discussion
and ‘consilia’) to support clinical decisions in difﬁcult-to-treat
cases needs, once more, to be emphasized.31
Financial support: No funding was received by the authors.
Conﬂict of interest: All authors have no conﬂicts of interest to
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